ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.599,57
-0,46%
S&P 500
5.222,68
0,16%
US Dollar vs BRL
5,1568
0,00%
Bitcoin
61.061,31
0,44%
Brent Oil
82,585
0,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Acer Therapeutics Inc (ACER)

  7. Acer Therapeutics Inc (ACER) Notícias

ACER

Acer Therapeutics (ACER)

Acer Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ACER
DataHoraFonteTítuloCódigoCompanhia
08/11/202318:13Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:ACERAcer Therapeutics Inc
08/11/202318:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACERAcer Therapeutics Inc
02/11/202309:51Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ACERAcer Therapeutics Inc
02/11/202309:30GlobeNewswire Inc.Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related ProposalsNASDAQ:ACERAcer Therapeutics Inc
10/10/202318:17Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:ACERAcer Therapeutics Inc
31/08/202308:30GlobeNewswire Inc.Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial ProductNASDAQ:ACERAcer Therapeutics Inc
30/08/202317:05GlobeNewswire Inc.Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical EuropeNASDAQ:ACERAcer Therapeutics Inc
14/08/202317:19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACERAcer Therapeutics Inc
14/08/202317:05GlobeNewswire Inc.Acer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:ACERAcer Therapeutics Inc
26/06/202310:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
26/06/202309:30GlobeNewswire Inc.Acer Therapeutics Receives $1 Million Capital Infusion from Chief Executive Officer and FounderNASDAQ:ACERAcer Therapeutics Inc
15/05/202318:29Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ACERAcer Therapeutics Inc
15/05/202318:10GlobeNewswire Inc.Acer Therapeutics Reports Q1 2023 Financial Results and Provides Corporate UpdateNASDAQ:ACERAcer Therapeutics Inc
01/05/202309:30GlobeNewswire Inc.Acer Therapeutics Announces OLPRUVA™ Commercial Launch Progressing Ahead of ScheduleNASDAQ:ACERAcer Therapeutics Inc
27/04/202307:25Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(2) (424b2)NASDAQ:ACERAcer Therapeutics Inc
14/04/202317:29Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:ACERAcer Therapeutics Inc
27/03/202317:18Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:ACERAcer Therapeutics Inc
27/03/202317:13Edgar (US Regulatory)Annual Report (10-k)NASDAQ:ACERAcer Therapeutics Inc
27/03/202317:01GlobeNewswire Inc.Acer Therapeutics Reports Q4 and Full Year 2022 Financial Results and Provides Corporate UpdateNASDAQ:ACERAcer Therapeutics Inc
23/03/202317:17Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:ACERAcer Therapeutics Inc
22/03/202309:30GlobeNewswire Inc.Acer Therapeutics Announces Data Presented at Society for Inherited Metabolic Disorders Annual Meeting Identifying Preferred Urea Cycle Disorder Treatment AttributesNASDAQ:ACERAcer Therapeutics Inc
22/03/202309:00GlobeNewswire Inc.Acer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:ACERAcer Therapeutics Inc
17/03/202309:30GlobeNewswire Inc.Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a TrialNASDAQ:ACERAcer Therapeutics Inc
16/03/202317:51Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ACERAcer Therapeutics Inc
15/03/202309:30GlobeNewswire Inc.Acer Therapeutics Announces Presentation of HCP Urea Cycle Disorder Treatment Preference Data at the Society for Inherited Metabolic Disorders Annual Meeting and Provides OLPRUVA™ Program UpdateNASDAQ:ACERAcer Therapeutics Inc
14/02/202319:17Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ACERAcer Therapeutics Inc
13/02/202310:30GlobeNewswire Inc.Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with MenopauseNASDAQ:ACERAcer Therapeutics Inc
31/01/202310:00PR Newswire (US)SWK Holdings Provides Portfolio Update Highlighting Recent AchievementsNASDAQ:ACERAcer Therapeutics Inc
09/01/202310:30GlobeNewswire Inc.Acer Therapeutics Highlights Key 2022 Achievements and Pipeline Advancements, and Provides Anticipated 2023 MilestonesNASDAQ:ACERAcer Therapeutics Inc
05/01/202310:30GlobeNewswire Inc.Acer Therapeutics Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the ProstateNASDAQ:ACERAcer Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ACER

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
OIBR3
OI ON
BOV
YDUQ3
ESTACIO PART ON
BOV
EMAE4
EMAE PN
BOV
MEAL3
IMC S/A ON
BOV
COGN3
COGNA ON
BOV
AERI3
Aeris Industria E Comerc... ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
UNIP6
UNIPAR PNB
BOV
PDGR3
PDG REALT ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados